Dr. Reddy's Reports Profit Boost

Indian drugmaker Dr. Reddy's has reported that profit in the third quarter surged by as much as 300% to INR2.8bn (US$62mn), mainly due to deals with Merck & Co on so-called 'authorised generic' formulations of Zocor (simvastatin) and Proscar (finasteride). However, the firm noted that 180-day Hatch-Waxman exclusivity will expire in December

To read the full article, please choose one of the following options: